grant
Preoptic/Hypothalamic Mechanisms of Sleep-Wake Regulation
Organization VA GREATER LOS ANGELES HEALTHCARE SYSTEMLocation LOS ANGELES, UNITED STATESPosted 1 Jan 2021Deadline 31 Dec 2028
VANIHUS FederalResearch GrantFY2026ABC Transport ProteinABC Transporter ProteinABC TransportersAD dementiaATP-Binding Cassette TransportersAdverse ExperienceAdverse eventAfter CareAfter-TreatmentAftercareAgeAgingAgonistAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimers DementiaAmericanAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAnxietyApopainApoptosis-Related Cysteine Protease Caspase 3Automobile DrivingBody TissuesCASP-3CASP3CASP3 geneCPP-32CPP32CPP32 proteinCPP32BCPP32betaCardiovascular DiseasesCellular MatrixCholesterolCholesterol HomeostasisChronicCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCysteine Protease CPP32Cysteine Protease CPP32 GeneCytoskeletal SystemCytoskeletonDREADDsDataDefectDepressive SyndromesDepressive disorderDiseaseDisorderDisturbance in cognitionDown-RegulationDrugsDysfunctionElderlyEquilibriumExhibitsF-ActinFiberFilamentous ActinFunctional disorderGliaGlial CellsHcrt proteinHcrt/ORXHcrts/ORXsHealthHortega cellHypothalamic structureHypothalamusImmunoblottingImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImpaired cognitionImpairmentInfectionInflammationInflammatoryKolliker's reticulumLinkLipopolysaccharidesLiver X ReceptorMedicationMiceMice MammalsMicrogliaModelingMurineMusNerve CellsNerve UnitNeural CellNeurocyteNeurogliaNeuroglial CellsNeuronsNon-neuronal cellNonneuronal cellObesityOpticsOutcomePARP Cleavage ProteasePARP Cleavage Protease GenePeripheralPharmaceutical PreparationsPhotometryPhysiopathologyPopulationPreoptic AreasPrimary Senile Degenerative DementiaResearchRiskRisk FactorsSCA-1SCA-1 GeneSREBP Cleavage Activity 1SREBP Cleavage Activity 1 GeneSeriesSleepSleep DeprivationSleep DisordersSleep disturbancesStressSystemTestingTimeTissuesTreatment PeriodVeteransWestern BlottingWestern ImmunoblottingYamaYama proteinaberrant sleepaccelerated agingaccelerated biological ageaccelerated biological agingadiposityadvanced ageage accelerationagedaged miceaged mouseagesaging processbalancebalance functionbasal forebraincardiovascular disordercaspase-3cholesterol metabolismcircadiancognitive dysfunctioncognitive losscorpulencecysteine protease P32decline in functiondecline in functional statusdeficient sleepdesigner receptors exclusively activated by designer drugsdetermine efficacydisrupted sleepdisturbed sleepdrivingdrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationelderly miceevaluate efficacyexamine efficacyexperimentexperimental researchexperimental studyexperimentsfall asleepfunctional declinefunctional status declinegeriatricgitter cellhigh riskhypnotichypocretinhypocretin/orexinhypocretins/orexinshypothalamicimpaired sleepimprovement on sleepinadequate sleepinflammation markerinflammatory markerinnovateinnovationinnovativeinsightinsufficient sleepintracellular skeletonirregular sleepmesogliamicroglial cellmicrogliocytemid lifemid-lifemiddle agemiddle agedmidlifemilitary veterannerve cementneural inflammationneuroinflammationneuroinflammatoryneuronalnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachold miceopticalorexinpathophysiologyperivascular glial cellpost treatmentpre-clinical studypreclinical studypreoptic regionprimary degenerative dementiaprogramsprotein blottingresponsesenile dementia of the Alzheimer typesenior citizensleep controlsleep debtsleep deficiencysleep deficitsleep diseasessleep disruptionsleep dysfunctionsleep dysregulationsleep illnesssleep improvementsleep insufficiencysleep losssleep onsetsleep patternsleep problemsleep regulationsleep routinesleep schedulesleep/wake disruptionsleep/wake disturbancesleep/wake patternssleep/wake regulationtreatment daystreatment durationveteran populationyounger age
Description preview
An estimated 54.1 million Americans, including 18.2 million Veterans (49% of the Veteran population),
are elderly and at higher risk for developing chronic sleep disturbance. Chronic insufficient or disrupted sleep
is associated with a spectrum of adverse health conditions, including anxiety, depressive disorders, obesity,
cardiovascular disease,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click